Biotechnology Company Announces Increased Demand For HIV Product

Trinity Biotech plc, a company in the field of human diagnostics and diabetes management solutions, has made a significant announcement that reveals its commitment to addressing pressing global health needs. The company, listed on Nasdaq under the ticker TRIB, recently reported a substantial increase in orders for its TrinScreen HIV product, leading to an upward revision of its 2024 sales forecast from $8 million to $10 million. $Trinity Biotech (TRIB.US)$